Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Combination Therapy With Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients With Chronic Idiopathic Myelofibrosis or Overlap Myelodysplastic/Myeloproliferative Disorders

NCT00274820 is registered in ClinicalTrials.gov with Case Comprehensive Cancer Center as lead sponsor.

NCT NCT00274820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00274820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Combination Therapy With Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients With Chronic Idiopathic Myelofibrosis or Overlap Myelodysplastic/Myeloproliferative Disorders
Lead sponsor
Case Comprehensive Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2005
Completion date
October 31, 2007
Enrollment
15 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloproliferative disorders, leukemia, myelodysplastic syndromes, myelodysplastic/myeloproliferative diseases